SHAREHOLDER ALERT: Investigation of Myovant Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - September 29, 2020) - Holzer & Holzer, LLC is investigating whether Myovant Sciences Ltd. (NYSE: MYOV) ("Myovant" or the "Company") complied with federal securities laws. On September 29, 2020, the Company announced results of an additional secondary endpoint from the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer. The price of Myovant's stock fell following the announcement.

If you purchased shares of Myovant and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Luke R. Kennedy, Esq. at lkennedy@holzerlaw.com, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64839